Leap Therapeutics (LPTX) presented updated preliminary data from Part B of the DeFianCe study, a Phase 2, open-label, global study of ...

On March 13, 2025, the US Court of Appeals for the Federal Circuit (Federal Circuit) issued a decision titled In Re: Xencor, Inc. (the ...

As artificial intelligence continues to evolve, especially here in the Bay Area, one lab is working to use AI technology to find the next effective weight loss drug.

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

The average treatment effect in the treated hazard ratio among those who received sotrovimab was 0.92 (95% confidence ...

The European Commission initially planned to launch this year’s first batch of Horizon Europe calls on global challenges and ...

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...

Alzinova AB (publ) (ticker: ALZ) today announces that the final analysis of data from the Phase 1b clinical study with the vaccine candidate ALZ-101, which included patients with early Alzheimer's dis ...

Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ETCompany ParticipantsBruce Mackle - LifeSci Advisors, ...

Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap ...

The Minnesota Board of Animal Health (MBAH) announced yesterday that testing as part of its milk surveillance program has ...

Different parts of the immune system have been targeted ... Antibodies against B cells Rituximab is a depleting antibody directed against CD20 on the surface of B cells, which has established ...